NIH funding Archives
Nov. 10, 2023—A Vanderbilt team team will develop and test new clinical decision support tools to facilitate timely prevention of potentially lethal hospital-acquired blood clots, also known as venous thromboembolism.
Nov. 1, 2023—In the largest study of its kind, researchers at Vanderbilt have identified unexpected alterations in the exocrine tissues of the pancreas that occur in the two major forms of diabetes, and with aging and obesity.
Oct. 27, 2023—Study seeks to better understand the mechanism behind the association between preeclampsia and other hypertensive disorders of pregnancy and cardiovascular disease.
Oct. 17, 2023—A Vanderbilt research team is conducting the first phase 1 clinical trial of a magnetic, flexible endoscope that has the potential to provide a safer alternative to standard colonoscopy, particularly for individuals with inflammatory bowel disease.
Oct. 4, 2023—Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Oct. 3, 2023—Vanderbilt University School of Medicine has received a grant to establish a research fellowship for genetic counselors that will prepare them to contribute more fully to the advancement of personalized medicine.
Aug. 17, 2023—Federal grant to help Vanderbilt researchers will pave the way for potential treatments for schizophrenia and autism spectrum disorder
Jul. 20, 2023—Researchers at Vanderbilt University Medical Center and the University of Cambridge have developed a method of or predicting gene expression in hard-to-access tissues like the brain from more accessible tissues, including whole blood.
Mar. 30, 2023—Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.
Mar. 23, 2023—A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.
Feb. 23, 2023—The National Institutes of Health has awarded a five-year, $5 million grant to Vanderbilt University Medical Center for continued support of the Brazil Regional Prospective Observational Research in Tuberculosis network, or RePORT-Brazil.